IDEAYA Biosciences, Inc.
General ticker "IDYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
IDEAYA Biosciences, Inc. follows the US Stock Market performance with the rate: 60.7%.
Estimated limits based on current volatility of 3.1%: low 32.51$, high 34.59$
Factors to consider:
- Total employees count: 131 as of 2024
- Top business risk factors: Limited operating history, Product safety concerns, Regulatory and compliance, Liquidity and credit risks, Early development dependency
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [23.11$, 47.32$]
- 2026-12-31 to 2027-12-31 estimated range: [19.48$, 41.11$]
Financial Metrics affecting the IDYA estimates:
- Negative: with PPE of -26.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.32 <= 0.01
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 2.28 > -0.63
- Positive: Shareholder equity ratio, % of 92.21 > 64.29
- Positive: Inventory ratio change, % of 0 <= 0
Short-term IDYA quotes
Long-term IDYA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $23.39MM | $7.00MM | $218.71MM |
| Operating Expenses | $157.81MM | $333.98MM | $378.02MM |
| Operating Income | $-134.43MM | $-326.98MM | $-159.31MM |
| Non-Operating Income | $21.47MM | $52.50MM | $45.62MM |
| R&D Expense | $129.51MM | $294.67MM | $314.70MM |
| Income(Loss) | $-112.96MM | $-274.48MM | $-113.70MM |
| Profit(Loss)* | $-112.96MM | $-274.48MM | $-113.70MM |
| Stockholders Equity | $621.09MM | $1,059.15MM | $1,022.93MM |
| Assets | $649.32MM | $1,124.09MM | $1,109.32MM |
| Operating Cash Flow | $-115.22MM | $-247.58MM | $-71.10MM |
| Capital expenditure | $2.37MM | $3.86MM | $2.37MM |
| Investing Cash Flow | $-158.46MM | $-502.56MM | $69.98MM |
| Financing Cash Flow | $362.72MM | $677.55MM | $29.78MM |
| Earnings Per Share** | $-1.96 | $-3.36 | $-1.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.